Abstract
Breast cancer is one of the most common type of cancers as well as a principal cause of cancer-related deaths in women worldwide. Although research has provided a better understanding and diagnosis of breast cancer, studies in breast cancer therapeutics are still far from satisfactory. Recent research on microRNAs (miRNAs) has implicated these tiny regulatory molecules in progression of breast cancer with the possibility of exploiting them as diagnostic and/or prognostic biomarkers. The loss of tumor suppressor miRNAs or overexpression of oncogenic miRNAs can lead to breast cancer tumorigenesis or metastasis. However, the next step – linking miRNAs to cancer therapeutics – is still under progression. The roles of miRNAs exhibit much potential in breast cancer therapy, but currently need to be further studied and evaluated in order to better understand how to apply laboratory results to clinical medicine. Here we provide an update on our current understanding of miRNAs as molecular targets for diagnosis, prognosis and therapy of breast cancers.
Keywords: microRNAs (miRNAs), breast cancer therapy, diagnostic biomarkers, prognostic biomarkers.
Current Pharmaceutical Design
Title:MicroRNAs in Breast Cancer Therapy
Volume: 20 Issue: 33
Author(s): Joy Tang, Aamir Ahmad and Fazlul H. Sarkar
Affiliation:
Keywords: microRNAs (miRNAs), breast cancer therapy, diagnostic biomarkers, prognostic biomarkers.
Abstract: Breast cancer is one of the most common type of cancers as well as a principal cause of cancer-related deaths in women worldwide. Although research has provided a better understanding and diagnosis of breast cancer, studies in breast cancer therapeutics are still far from satisfactory. Recent research on microRNAs (miRNAs) has implicated these tiny regulatory molecules in progression of breast cancer with the possibility of exploiting them as diagnostic and/or prognostic biomarkers. The loss of tumor suppressor miRNAs or overexpression of oncogenic miRNAs can lead to breast cancer tumorigenesis or metastasis. However, the next step – linking miRNAs to cancer therapeutics – is still under progression. The roles of miRNAs exhibit much potential in breast cancer therapy, but currently need to be further studied and evaluated in order to better understand how to apply laboratory results to clinical medicine. Here we provide an update on our current understanding of miRNAs as molecular targets for diagnosis, prognosis and therapy of breast cancers.
Export Options
About this article
Cite this article as:
Tang Joy, Ahmad Aamir and Sarkar H. Fazlul, MicroRNAs in Breast Cancer Therapy, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128205239
DOI https://dx.doi.org/10.2174/1381612820666140128205239 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Significance of COX-2 and COX-2 Inhibitors in Liver Fibrosis and Liver Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Traumatic Brain Injury as a Risk Factor for Alzheimer’s Disease: Is Inflammatory Signaling a Key Player?
Current Alzheimer Research The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer
Current Medicinal Chemistry Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition
Current Cancer Drug Targets Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Current Pharmaceutical Design PREFACE
Anti-Cancer Agents in Medicinal Chemistry Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Nanomedicine for Cancer Therapy Using Autophagy: An Overview
Current Topics in Medicinal Chemistry Therapeutic Potential of Alpinia officinarum
Mini-Reviews in Medicinal Chemistry Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Graphical Abstracts
Anti-Cancer Agents in Medicinal Chemistry Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology The Role of Image Guided Radiotherapy in the Treatment of Soft Tissue Sarcoma
Current Cancer Therapy Reviews Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9
Combinatorial Chemistry & High Throughput Screening Comparing High LET <sup>227</sup>Th- and Low LET <sup>177</sup>Lu-trastuzumab in Mice with HER-2 Positive SKBR-3 Xenografts
Current Radiopharmaceuticals Sentinel Node Biopsy in Early Breast Cancer
Medicinal Chemistry